Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 20, 2026

Oral Hypoglycemic Agents: Biguanides and Glitazones
01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

594

[Biguanide].

Akio Ohta, Yasushi Tanaka

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |March 28, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Metformin is a first-line treatment for type 2 diabetes, effectively lowering blood glucose. It works by reducing liver glucose production and increasing glucose uptake, though its precise mechanism is still being researched.

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    594
    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    594

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effects of Carbonated and Electrolyte-Added Water on Body Fluid Regulation and Ingestive Behavior During Ad Libitum Rehydration Following Mild Hypohydration.

    Nutrients·2026
    Same author

    Exploring plasma cell-free RNA biomarkers for predicting immune checkpoint inhibitor efficacy in gastric cancer: a translational sub-study of the KSCC VOYAGER phase II trial.

    International journal of clinical oncology·2026
    Same author

    Cooperative Host-Guest Complexation in Densely Assembled Host Structures on Surfaces Revealed at the Single-Molecular Level.

    Journal of the American Chemical Society·2026
    Same author

    Production of <sup>64</sup>Cu and <sup>67</sup>Cu with accelerator neutrons by deuterons and their separation from zinc.

    Frontiers in nuclear medicine·2025
    Same author

    Identification of anti-mouse PD-1 agonist antibodies that inhibit T cell activation.

    Frontiers in immunology·2025
    Same author

    Circulating tumor DNA monitoring detects minimal residual disease and predicts outcomes in patients with esophageal adenocarcinoma or squamous cell carcinoma after esophagectomy.

    BJC reports·2025

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Metabolic Diseases

    Context:

    • Metformin is a widely recommended first-line oral antihyperglycemic agent for type 2 diabetes by major diabetes associations.
    • Its glucose-lowering efficacy is well-established, impacting key metabolic pathways.
    • Understanding the precise molecular mechanisms remains an active area of research.

    Purpose:

    • To elucidate the multifaceted mechanisms by which metformin exerts its glucose-lowering effects.
    • To highlight the role of AMP-activated protein kinase (AMPK) activation in metformin's action.
    • To detail the potential risks and contraindications associated with metformin use, particularly lactic acidosis.

    Summary:

    • Metformin lowers blood glucose by decreasing hepatic glucose production and enhancing peripheral glucose uptake in muscle tissue.

    Related Experiment Videos

    Last Updated: Jan 20, 2026

    Oral Hypoglycemic Agents: Biguanides and Glitazones
    01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    594
  • It also increases fatty acid oxidation in adipose tissue, contributing to its metabolic benefits.
  • The drug is believed to activate hepatic AMP-activated protein kinase (AMPK) and suppress liver glucagon signaling via mitochondrial respiratory chain inhibition.

    • Impact:

    • Metformin's established efficacy and safety profile make it a cornerstone in type 2 diabetes management.
    • Further understanding of its mechanism can lead to optimized therapeutic strategies and potentially new drug development.
    • Awareness of contraindications, such as risk factors for lactic acidosis, is crucial for safe patient care.